Document is current

Article History

Received: 5 June 2025

Accepted: 1 September 2025

First Online: 18 September 2025

Declarations

:

: JB received support from Kyowa Kirin for the data collection and analysis and medical writing for the current study and paper, and has received advisory board consultancy fees and honouraria from Kyowa Kirin. EM has been a clinical investigator on other burosumab studies. MS has received honouraria/speaking fees and funding for conference attendance from UCB. GPRC has received medical writing, consultation fees, honouraria, support for conference attendance and funding for a research nurse from Kyowa Kirin, and honouraria from Pharmacosmos. MR has received funding to attend conference from Eli Lilly. RK has received payments from KKI for data collection and analysis, medical writing, consultancy, speaker honouraria and travel support for conference attendance. DS contracted to Bionical Emas Ltd and received payment for services relating data collection and resulting publications in the current study. RD is a full-time employee of Bionical Emas Ltd, which received payment for services relating to data collection and resulting publications in the current study. BJ, GL and VH are employees of Kyowa Kirin. AB, HB and MN were employed by, or contracted to, Chilli Consulting Ltd at the time of the study and received payment from Kyowa Kirin for data analysis and medical writing. RL, GK, JW, LM, SS, YL and RK have no conflicts of interest to declare.

: The study protocol and supporting documents were approved by the East Midlands – Leicester South Research Ethics Committee (ref 23/EM/0078) and the NHS Health Research Authority and Health Research Wales (IRAS project ID 321609; 9 May 2023).

: Informed consent was not collected from patients as no identifiable data were accessed outside the direct care team.